Khuyến nghị về quản lý bệnh viêm cột sống dính khớp theo ASAS/EULAR

Khan MA (2002) Update on spondyloarthropathies. Ann Intern Med 135: 896–907 Sieper J, Braun J, Rudwaleit M et al. (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61 [Suppl 3]: 8–18 Braun J, Bollow M, Remlinger G et al. (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41: 58–67 Edmunds L, Elswood J, Kennedy LG, Calin A (1991) Primary ankylosing spondylitis, psoriatic and enteropathic spondyloarthropathy: a controlled analysis. J Rheumatol 18: 696–698 Vilar MJ, Cury SE, Ferraz MB et al. (1997) Renal abnormalities in ankylosing spondylitis. Scand J Rheumatol 26: 19–23 Zink A, Braun J, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis – results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27: 613–622 Karberg K, Zochling J, Sieper J et al. (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32: 1290–1298 Donnelly S, Doyle DV, Denton A et al. (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53: 117–121 Braun J, Pincus T (2002) Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20 [Suppl 28]: S16–S22 Braun J, Brandt J, Listing J et al. (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359: 1187–1193 Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346: 1349–1356 Van der Heijde D, Kivitz A, Schiff M et al. (2005) Adalimumab therapy results in significant reduction of signs and symptoms in subjects with ankylosing spondylitis: the ATLAS trial. Arthritis Rheum 52 [Suppl]: S281 Haibel H, Niewerth M, Brandt J et al. (2004) Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12. Z Rheumatol 63: 393–401 Baraliakos X, Listing J, Rudwaleit M et al. (2005) Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor alpha antibody infliximab. Ann Rheum Dis 64: 1462–1466 Zochling J, van der Heijde D, Burgos-Vargas R et al. (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65: 442–452 Zochling J, van der Heijde D, Dougados M, Braun J (2006) Current evidence for the management of ankylosing spondylitis. Ann Rheum Dis 65: 423–432 Dougados M, Betteridge N, Burmester GR et al. (2004) EULAR standardized operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 63: 1172–1176 Hedges LV (1982) Fitting continuous models to effect size data. J Educat Stat 7: 245–270 Cohen J (1988) Statistical power analysis for the behavioural sciences, 2nd ed. Erlbaum, Hillsdale/NJ Cook RJ, Sackett DL (1995) The number needed to treat: a clinically useful measure of treatment effect. BMJ 310: 452–454 Shekelle PG, Woolf SH, Eccles M, Grimshaw J (1999) Clinical guidelines: Developing guidelines. BMJ 318: 593–596 Amor B, Santos RS, Nahal R et al. (1994) Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 21: 1883–1887 Guillemin F, Briancon S, Pourel J, Gaucher A (1990) Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors. Arthritis Rheum 33: 1001–1006 Ward MM (2002) Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 29: 1420–1425 Doran MF, Brophy S, MacKay K et al. (2003) Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 30: 316–320 Van der Heijde D, Wanders A, Mielants H et al. (2004) Prediction of progression of radiographic damage over 4 years in patients with ankylosing spondylitis. Ann Rheum Dis 63 [Suppl 1]: 98 Rudwaleit M, Listing J, Brandt J et al. (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63: 665–670 Van der Heijde D, van der Linden S, Dougados M et al. (1999) Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol 26: 1003–1005 Van der Heijde D, Bellamy N, Calin A et al. (1997) Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24: 2225–2229 Wanders A, Landewe R, Spoorenberg A et al. (2004) Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order. Ann Rheum Dis 63: 1601–1604 Dagfinrud H, Hagen K (2001) Physiotherapy interventions for ankylosing spondylitis. Cochrane Database of Systematic Reviews (4): CD002822 Kraag G, Stokes B, Groh J et al. (1990) The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis – a randomized controlled trial. J Rheumatol 17: 228–233 Hidding A, van der Linden S, Boers M et al. (1993) Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. Arthritis Care Res 6: 117–125 Analay Y, Ozcan E, Karan A et al. (2003) The effectiveness of intensive group exercise on patients with ankylosing spondylitis. Clin Rehabil 17: 631–636 Lim H-J, Moon Y-I, Lee MS (2005) Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. Rheumatol Int 25: 225–229 Sweeney S, Taylor G, Calin A (2002) The effect of a home based exercise intervention package on outcome in ankylosing spondylitis: a randomized controlled trial. J Rheumatol 29: 763–766 Van Tubergen A, Landewe R, van der Heijde D et al. (2001) Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 45: 430–438 Van Tubergen A, Boonen A, Landewe R et al. (2002) Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 47: 459–467 Barlow JH, Barefoot J (1996) Group education for people with arthritis. Pt Educat Counsel 27: 257–267 Basler HD, Rehfisch HP (1991) Cognitive-behavioral therapy in patients with ankylosing spondylitis in a German self-help organization. J Psychosom Res 35: 345–354 Krauth C, Rieger J, Bonisch A, Ehlebracht-Konig I (2003) Costs and benefits of an education program for patients with ankylosing spondylitis as part of an inpatient rehabilitation programs-study design and first results. Z Rheumatol 62 [Suppl 2]: 14–16 Wanders A, van der Heijde D, Landewé R et al. (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum 52: 1756–1765 Zhang W, Doherty M, Arden N et al. (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64: 669–681 Deeks JJ, Smith LA, Bradley MD (2002) Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 325: 619–623 Konstam MA, Weir MR, Reicin A et al. (2001) Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104: 2280–2288 Bresalier RS, Sandler RS, Quan H et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102 Solomon SD, McMurray JJV, Pfeffer MA et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080 Nussmeier NA, Whelton AA, Brown MT et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081–1091 Juni P, Nartey L, Reichenbach S et al. (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364: 2021–2029 Lewis SC, Langman MJ, Laporte JR et al. (2002) Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 54: 320–326 Zhang W, Jones A, Doherty M (2004) Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials. Ann Rheum Dis 63: 901–907 Maugars Y, Mathis C, Vilon P, Prost A (1992) Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. Arthritis Rheum 35: 564–568 Luukkainen R, Nissila M, Asikainen E et al. (1999) Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin Exp Rheumatol 17: 88–90 Chen J, Liu C (2005) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2: CD004800 Kirwan J, Edwards A, Huitfeldt B et al. (1993) The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 32: 729–733 Lehtinen A, Leirisalo-Repo M, Taavitsainen M (1995) Persistence of enthesopathic changes in patients with spondyloarthropathy during a 6-month follow-up. Clin Exp Rheumatol 13: 733–736 Chen J, Liu C (2004) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 3: CD004524 Altan L, Bingol U, Karakoc Y et al. (2001) Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 30: 255–259 Roychowdhury B, Bintley-Bagot S, Bulgen DY et al. (2002) Is methotrexate effective in ankylosing spondylitis? Rheumatology 41: 1330–1332 Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M et al. (2004) Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 31: 1568–1574 Ortiz Z (2004) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews 4 Maksymowych WP, Jhangri GS, Fitzgerald AA et al. (2002) A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46: 766–773 Maksymowych WP, Jhangri GS, LeClercq S et al. (1998) An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 25: 714–717 Maksymowych WP, Lambert R, Jhangri GS et al. (2001) Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 28: 144–155 Adami S, Bhalla AK, Dorizzi R et al. (1987) The acute-phase response after bisphosphonate administration. Calcif Tiss Int 41: 326–331 Wei JC, Chan TW, Lin H et al. (2003) Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol 30: 2627–2631 Huang F, Gu J, Zhao W et al. (2002) One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Care Res 47: 15 Davis JC Jr, van der Heijde D, Braun J et al. (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48: 3230–3236 Brandt J, Khariouzov A, Listing J et al. (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48: 1667–1675 Calin A, Dijkmans BA, Emery P et al. (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63: 1594–1600 Van der Heijde D, Dijkmans B, Geusens P et al. (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized controlled trial (ASSERT). Arthritis Rheum 52: 582–591 Haibel H, Brandt HC, Rudwaleit M et al. (2004) Efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: preliminary results of an open-label, 20-week trial. Arthritis Rheum 50 [Suppl]: S217 Braun J, Brandt J, Listing J et al. (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64: 229–234 Nikas SN, Alamanos Y, Voulgari PV et al. (2005) Infliximab therapy in ankylosing spondylitis: an observational study. Ann Rheum Dis 64: 940–942 Van den Bosch F, Devinck M, Kruithof E et al. (2004) A prospective long-term study of the efficacy and safety of infliximab in 107 patients with spondyloarthropathy. Arthritis Rheum 50 [Suppl]: S611 Baraliakos X, Brandt J, Listing J et al. (2004) Clinical response to long-term therapy with infliximab in patients with ankylosing spondylitis – results after 3 years. Arthritis Rheum 50 [Suppl]: S615 Baraliakos X, Listing J, Brandt J et al. (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7: R439–R444 Maini RN, Breedveld FC, Kalden JR et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563 Elliott MJ, Maini RN, Feldmann M et al. (1994) Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344: 1125–1127 Braun J, Pham T, Sieper J et al. (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62: 817–824 Lee J-H, Slifman NR, Gershon SK et al. (2002) Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor a antagonists infliximab and etanercept. Arthritis Rheum 46: 2565–2570 Slifman NR, Gershon SK, Lee J-H et al. (2003) Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor a-neutralizing agents. Arthritis Rheum 48: 319–324 Keystone EC (2004) Safety issues related to emerging therapies for rheumatoid arthritis. Clin Exp Rheumatol 22 [Suppl 35]: S148–S150 Baeten D, Kruithof E, van den Bosch F et al. (2003) Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 62: 829–834 Mohan N, Edwards ET, Cupps TR et al. (2001) Demyelination occurring during anti-tumor necrosis factor a therapy for inflammatory arthritides. Arthritis Rheum 44: 2862–2869 Ferraccioli GF, Assaloni R, Perin A et al. (2002) Drug-induced systemic lupus erythematosus and TNF-a blockers (multiple letters). Lancet 360: 645–646 Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359: 579–580 Cairns AP, Duncan MKJ, Hinder AE, Taggart AJ (2002) New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 61: 1031–1032 Chung ES, Packer M, Lo KH et al., Anti-TNF Therapy Against Congestive Heart Failure Investigators (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107: 3133–3140 Coletta AP, Clark AL, Banarjee P, Cleland JG (2002) Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Failure 4: 559–561 Wolfe F, Michaud MS (2004) Congestive heart failure in rheumatoid arthritis: rates, predictors and the effect of anti-TNF therapy. Am J Med 116: 311 Kobelt G, Andlin-Sobocki P, Brophy S et al. (2004) The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology 43: 1158–1166 Singh G, Tandon N, Bala M (2004) A cost efficacy analysis on anti-TNF therapy in ankylosing spondylitis. Arthritis Rheum 50 [Suppl]: S613 Sweeney S, Gupta R, Taylor G, Calin A (2001) Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol 28: 1862–1866 Furnes O, Lie SA, Espehaug B et al. (2001) Hip disease and the prognosis of total hip replacements. A review of 53,698 primary total hip replacements reported to the Norwegian Arthroplasty Register 1987–99. J Bone Joint Surg Br 83: 579–586 Brinker MR, Rosenberg AG, Kull L, Cox DD (1996) Primary noncemented total hip arthroplasty in patients with ankylosing spondylitis: clinical and radiographic results at an average follow-up period of 6 years. J Arthroplasty 11: 802–812 Bhan S, Malhotra R (1996) Bipolar hip arthroplasty in ankylosing spondylitis. Arch Ortho Trauma Surg 115: 94–99 Diaz de Rada P, Barroso-Diaz JL, Valenti JR (2004) Follow-up of the outcome of hip arthroplasty in patients with ankylosing spondylitis. Rev Ortop Traumatol 48: 340–344 Sochart DH, Porter ML (1997) Long-term results of total hip replacement in young patients who had ankylosing spondylitis. Eighteen to thirty-year results with survivorship analysis. J Bone Joint Surg Am 79: 1181–1189 Van Royen BJ, de Kleuver M, Slot GH (1998) Polysegmental lumbar posterior wedge osteotomies for correction of kyphosis in ankylosing spondylitis. Eur Spine J 7: 104–110 Jordan KM, Arden NK, Doherty M et al. (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62: 1145–1155 Anderson JJ, Baron G, van der Heijde D et al. (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44: 1876–1886 Brandt J, Listing J, Sieper J et al. (2004) Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 63: 1438–1444 Zhang W, Doherty M, Arden N et al. (2005) Alternative method of measuring the strength of recommendation for evidence based guidelines. Ann Rheum Dis 64: 1462–1466 Atkins D, Best D, Briss PA et al. (2004) Grading quality of evidence and strength of recommendations. BMJ 328: 1490 Atkins D, Eccles M, Flottorp S et al. (2004) Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Services Research 4: 38 Schunemann HJ, Best D, Vist G, Oxman AD, for The GRADE Working Group (2003) Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ 169: 677–680 Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27: 361–368